Summary
U.S. stock index futures opened mixed on Thursday as investors weighed ongoing geopolitical friction in the Middle East alongside corporate results and further indications that inflationary pressures in the United States may be easing. By 08:10 ET, S&P 500 futures were down 0.3%, Nasdaq 100 futures slipped 1%, and Dow Jones futures edged up 0.1%.
Earnings and sector moves
Semiconductor shares came under pressure even after Taiwan Semiconductor Manufacturing Co. (TSMC) delivered an exceptional quarter. TSMC reported second-quarter profit that rose 77% year-on-year to a record level and posted earnings per share of $4.31, topping estimates of $3.80. Despite the upbeat results, the company's stock fell about 4% in premarket trading after investors reacted to an expanded capital expenditure plan and the attendant risk of near-term margin pressure.
The cautious response at TSMC rippled through the chip sector. Nvidia, identified as TSMC’s largest customer, declined 1.3%, while AMD, Intel and Micron Technology retreated in a range between 1.9% and 2.7% as traders considered the implications of increased industry investment.
In contrast, parts of the healthcare complex advanced. UnitedHealth Group climbed 7.6% after reporting a stronger-than-expected second quarter. The health insurer posted adjusted earnings of $6.38 per share, comfortably beating analyst estimates, and revenue also exceeded forecasts as broad strength across its healthcare businesses appeared to reassure investors following months of uncertainty in the managed care sector.
Abbott Laboratories rose 4.4% after beating expectations on both revenue and earnings and saying sales of its continuous glucose monitoring products are on track to return to double-digit growth, which helped alleviate concerns about weakening demand for those devices.
Other corporate developments
GE Aerospace slipped 4.3% despite reporting a quarterly result that topped Wall Street estimates. The pullback was attributed to profit-taking after a strong run in the shares and analyst commentary suggesting much of the positive outlook may already have been reflected in the price.
U.S. Bancorp fell 2.4% even though it reported record quarterly revenue and earnings that beat expectations, indicating that the bank’s strong performance had likely been priced into the stock ahead of the release.
Meanwhile, the psychedelic drug development cohort drew buying interest after an acquisition agreement involving Eli Lilly and AtaiBeckley. AtaiBeckley surged more than 30% in premarket trading, while GH Research gained nearly 19% and Compass Pathways advanced over 7% as optimism spread through the group.
Market context
Traders continued to balance geopolitical concerns with corporate results and readings suggesting softer inflationary pressures in the U.S. The mixed premarket moves reflected rotation among sectors: health insurers and selected medical-device names led gains, while semiconductors, aerospace and banking names showed weakness in early trade.
Looking ahead
Market participants will likely continue to monitor corporate reports for signs that earnings trends and capital spending plans are consistent with sustained margin improvement, while also keeping an eye on geopolitical developments and inflation dynamics that could influence policy expectations and risk appetite.